FOXP3 and hepatocellular carcinoma: We found that peptide F393–403, a truncated version of peptide F393–407, inhibited FOXP3–NFAT interaction and improved effector T-cell functions in response to TCR stimulation and delayed tumor growth in a model of hepatocellular carcinoma [23].